Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Fabrice André, Ruth O’Regan, Mustafa Özgüroğlu, Masakazu Toi, Binghe Xu, Guy Jérusalem, Norikazu Masuda, Sharon Wilks, Francis P. Arena, Claudine Isaacs,

The Lancet Oncology · 2014 · 491 citations · 34 references

Concepts

References

34